TESTOSTERONE CYPIONATE (TESTOSTERONE CYPIONATE)
- Androgen deficiency
- Gonadotropin releasing factor deficiency
- Male hypogonadism
- Bilateral anorchia
- Bilateral orchiectomy
- Chemotherapy-induced hypogonadism
- Cryptorchidism
- Klinefelter's syndrome
- Primary hypogonadism due to bilateral torsion of testes
- Primary hypogonadism due to orchitis
- Testosterone Cypionate Intramuscular Oil
- Testosterone Cypionate Im Oil
- Depo-testosterone Intramuscular Oil
- By Indication
100 mg/mL intramuscular oil
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
200 mg/mL intramuscular oil
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
50 mg/mL intramuscular oil
- Dosage information is not available
100 mg/mL intramuscular oil
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
200 mg/mL intramuscular oil
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
50 mg/mL intramuscular oil
- Dosage information is not available
100 mg/mL intramuscular oil
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
200 mg/mL intramuscular oil
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
Androgen deficiency
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Bilateral anorchia
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Bilateral orchiectomy
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Chemotherapy-induced hypogonadism
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Cryptorchidism
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Gonadotropin releasing factor deficiency
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Male hypogonadism
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Primary hypogonadism due to bilateral torsion of testes
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
Primary hypogonadism due to orchitis
- Inject 0.5 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 4 milliliters (400 mg) by intramuscular route every 4 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Malignant tumor of male breast
- Pregnancy
- Prostatic carcinoma
Contraindicated
- Acute myocardial infarction
- Benign prostatic hyperplasia
- Cerebrovascular accident
- Chronic pulmonary disease
- Erythrocytosis
- Hypercholesterolemia
- Kidney disease with reduction in GFR
- Polycythemia vera
- Pulmonary thromboembolism
- Venous thrombosis
Severe
Moderate
- Chronic heart failure
- Diabetes mellitus
- Disease of liver
- Edema
- Gynecomastia
- Humoral hypercalcemia of malignancy
- Hypertension
- Obesity
- Sleep apnea
TESTOSTERONE CYPIONATE (TESTOSTERONE CYPIONATE)
- Androgen deficiency
- Gonadotropin releasing factor deficiency
- Male hypogonadism
- Bilateral anorchia
- Bilateral orchiectomy
- Chemotherapy-induced hypogonadism
- Cryptorchidism
- Klinefelter's syndrome
- Primary hypogonadism due to bilateral torsion of testes
- Primary hypogonadism due to orchitis
- Amenorrhea
- Bladder irritability
- Irregular menstrual periods
- Priapism
- Urinary tract infection
- Virilism
- Gynecomastia
- Mastalgia
More Frequent
Severe
Less Severe
- Benign prostatic hyperplasia
- Disease of liver
- Dizziness
- Edema
- Epididymitis
- Fatigue
- Flushing
- Hypercalcemia
- Hypertension
- Nausea
- Prostatic carcinoma
- Raised prostate specific antigen
- Sleep apnea
- Vomiting
- Abdominal pain with cramps
- Acne vulgaris
- Administration site infection
- Diarrhea
- Erectile dysfunction
- Headache disorder
- Increased pubic hair
- Injection site sequelae
- Insomnia
- Libido changes
- Testicular atrophy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Cerebrovascular accident
- Deep venous thrombosis
- Drug-induced hepatitis
- Erythrocytosis
- Heart failure
- Hepatic necrosis
- Leukopenia
- Malignant neoplasm of liver
- Peliosis hepatis
- Pulmonary thromboembolism
- Suicidal ideation
- Venous thrombosis
Less Severe
- Aggressive behavior
- Anorexia
- Depression
- Hostility
- Hypercholesterolemia
- Irritability
- Oligospermia
Contraindicated
None
Severe Precaution
Testosterone (Inj)
Safety and efficacy not established age<12 years. May cause premature epiphyseal closure.
- 1 Day – 12 Years
- Safety and efficacy not established age<12 years. May cause premature epiphyseal closure.
Management or Monitoring Precaution
None
Testosterone
- Severity Level:
1
- Additional Notes: Androgens contraindicated in pregnancy; risk of virilization of female fetus.
Contraindicated
Testosterone
Poss sev adv effects, premature epiphyseal closure, virilization of females
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Poss sev adv effects, premature epiphyseal closure, virilization of females |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Testosterone
General-Avoid use in the elderly unless indicated for confirmed hypogonadism. Urogenital-Increased risk of acute kidney injury. May exacerbate prostate cancer. Cardiovascular-Reports of venous thromboembolism, deep vein thrombosis and pulmonary embolism. Possible increased risk of atrial fibrillation.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
Androgen deficiency | |
E29.1 | Testicular hypofunction |
Bilateral anorchia | |
Q55.0 | Absence and aplasia of testis |
Chemotherapy-induced hypogonadism | |
E29.1 | Testicular hypofunction |
Cryptorchidism | |
Q53 | Undescended and ectopic testicle |
Q53.0 | Ectopic testis |
Q53.00 | Ectopic testis, unspecified |
Q53.01 | Ectopic testis, unilateral |
Q53.02 | Ectopic testes, bilateral |
Q53.1 | Undescended testicle, unilateral |
Q53.10 | Unspecified undescended testicle, unilateral |
Q53.11 | Abdominal testis, unilateral |
Q53.111 | Unilateral intraabdominal testis |
Q53.112 | Unilateral inguinal testis |
Q53.12 | Ectopic perineal testis, unilateral |
Q53.13 | Unilateral high scrotal testis |
Q53.2 | Undescended testicle, bilateral |
Q53.20 | Undescended testicle, unspecified, bilateral |
Q53.21 | Abdominal testis, bilateral |
Q53.211 | Bilateral intraabdominal testes |
Q53.212 | Bilateral inguinal testes |
Q53.22 | Ectopic perineal testis, bilateral |
Q53.23 | Bilateral high scrotal testes |
Q53.9 | Undescended testicle, unspecified |
R39.83 | Unilateral non-palpable testicle |
R39.84 | Bilateral non-palpable testicles |
Gonadotropin releasing factor deficiency | |
E23.3 | Hypothalamic dysfunction, not elsewhere classified |
Klinefelter's syndrome | |
Q98.0 | Klinefelter syndrome karyotype 47, XXY |
Q98.1 | Klinefelter syndrome, male with more than two X chromosomes |
Q98.4 | Klinefelter syndrome, unspecified |
Male hypogonadism | |
E29.1 | Testicular hypofunction |
Primary hypogonadism due to bilateral torsion of testes | |
E29.1 | Testicular hypofunction |
Primary hypogonadism due to orchitis | |
E29.1 | Testicular hypofunction |
0-9 | A-Z |
---|---|
E23.3 | Hypothalamic dysfunction, not elsewhere classified |
E29.1 | Testicular hypofunction |
E29.1 | Testicular hypofunction |
E29.1 | Testicular hypofunction |
E29.1 | Testicular hypofunction |
E29.1 | Testicular hypofunction |
Q53 | Undescended and ectopic testicle |
Q53.0 | Ectopic testis |
Q53.00 | Ectopic testis, unspecified |
Q53.01 | Ectopic testis, unilateral |
Q53.02 | Ectopic testes, bilateral |
Q53.1 | Undescended testicle, unilateral |
Q53.10 | Unspecified undescended testicle, unilateral |
Q53.11 | Abdominal testis, unilateral |
Q53.111 | Unilateral intraabdominal testis |
Q53.112 | Unilateral inguinal testis |
Q53.12 | Ectopic perineal testis, unilateral |
Q53.13 | Unilateral high scrotal testis |
Q53.2 | Undescended testicle, bilateral |
Q53.20 | Undescended testicle, unspecified, bilateral |
Q53.21 | Abdominal testis, bilateral |
Q53.211 | Bilateral intraabdominal testes |
Q53.212 | Bilateral inguinal testes |
Q53.22 | Ectopic perineal testis, bilateral |
Q53.23 | Bilateral high scrotal testes |
Q53.9 | Undescended testicle, unspecified |
Q55.0 | Absence and aplasia of testis |
Q98.0 | Klinefelter syndrome karyotype 47, XXY |
Q98.1 | Klinefelter syndrome, male with more than two X chromosomes |
Q98.4 | Klinefelter syndrome, unspecified |
R39.83 | Unilateral non-palpable testicle |
R39.84 | Bilateral non-palpable testicles |